Standout Papers
Citation Impact
Citing Papers
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period
2006
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)
2008
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism
2012
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis
2009
Pancreatic cancer
2004 Standout
Mechanisms of Thrombus Formation
2008 Standout
IDH1andIDH2Mutations in Gliomas
2009 Standout
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Ambulatory management of pulmonary embolism: a pragmatic evaluation
2010
A pilot study of central venous catheter survival in cancer patients using low‐molecular‐weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study)
2007
The biology and management of non-small cell lung cancer
2018 StandoutNature
Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients
2009
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters
2009
Perioperative Management of Antithrombotic Therapy
2012 Standout
Glioblastoma and Other Malignant Gliomas
2013 Standout
Reporting Standards for Endovascular Treatment of Lower Extremity Deep Vein Thrombosis
2006
Antithrombotic Therapy for VTE Disease
2016 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Thromboembolic disease in patients with high-grade glioma
2012
The role of vena caval filters in the management of venous thromboembolism
2004
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients
2004
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Prognostic Value of ECG Among Patients with Acute Pulmonary Embolism and Normal Blood Pressure
2009
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Treatment of Deep-Vein Thrombosis
2004
A meta‐analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment
2007
Lung cancer: current therapies and new targeted treatments
2016 Standout
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study
2015
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial
2012
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Platelet Activation and Atherothrombosis
2007 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
2011
Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy: The Balance of Benefits and Harms
2007
The treatment of venous thromboembolism with low-molecular-weight heparins
2012
Guidelines on the use and monitoring of heparin
2006
Use of Antithrombotic Agents During Pregnancy
2004
Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism
2006
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Malignant Gliomas in Adults
2008 Standout
Alzheimer's disease
2006 Standout
Direct Oral Anticoagulants in Patients With VTE and Cancer
2014
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma
2010
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Microenvironmental regulation of metastasis
2008 Standout
Home Therapy of Venous Thrombosis with Long-term LMWH versus Usual Care: Patient Satisfaction and Post-thrombotic Syndrome
2009
Idarucizumab for Dabigatran Reversal
2015 Standout
Development of a Research Agenda for Inferior Vena Cava Filters: Proceedings from a Multidisciplinary Research Consensus Panel
2009
Outcomes and Cost of Deep Venous Thrombosis Among Patients With Cancer
2004
Antithrombotic Therapy in Neonates and Children
2008
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
2016
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
2012
Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism
2009
Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer
2006
Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis
2014
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
Long-term Treatment of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Tinzaparin): A Prospective Randomized Trial
2005
Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review
2009
Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation
2004
Pancreatic cancer and thromboembolic disease
2004
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
2009
Hemorrhagic Complications of Anticoagulant Treatment
2004
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2004 Standout
Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease
2004
Pancreatic cancer
2011 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Acute Cerebral Infarction during Combination Chemotherapy with S-1 and Cisplatin for a Young Patient with a Mucin-Producing Adenocarcinoma of the Stomach
2006
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Micrometastatic Disease and Metastatic Outgrowth: Clinical Issues and Experimental Approaches
2009
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
2014
Anticoagulation: Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
2009
Trousseau's syndrome: multiple definitions and multiple mechanisms
2007
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
2007
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning
2010
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
2015
The management of venous thromboembolism in cancer patients
2007
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
2005
Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism
2004
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials
2009
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
2014
Risk factors for venous thromboembolic events in cancer patients
2005
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
2013 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2013
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
2005
Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism
2005
Cardiovascular Complications of Cancer Therapy
2004
Works of Chris Bowden being referenced
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Real-time pharmacokinetics guiding clinical decisions
2004
Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism
2005
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2013